Literature DB >> 27740519

 Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease.

Agnieszka Zwolak1, Agnieszka Szuster-Ciesielska2, Jadwiga Daniluk1, Justyna Semeniuk2, Martyna Kandefer-Szerszen2.   

Abstract

Background. Chemerin and retinol binding protein-4 (RBP-4) are adipokines which may play a role in the progression of NAFLD. It has been also suggested that cytokeratin-18 (CK-18) could be a marker of hepatocyte caspase-directed death while transgelin-2 production could reflect stage of liver fibrosis. The aim of this study was to evaluate the level of the above adipokines in sera of patients with NAFLD and determine the relation between the level of transgelin-2 and fibrosis-4 index (FIB-4).
MATERIAL AND METHODS: Ninety-five subjects included initially to the study were divided into four groups: (I) prediabetics, obese with NAFLD and metabolic syndrome (MS), (II) lean with NAFLD and without MS, (III) obese without NAFLD and MS, and (IV) healthy individuals. We determined the levels of chemerin, RBP-4, transgelin-2 and CK-18 fragments in sera of patients with NAFLD. Moreover, we examined if the levels of CK-18 fragments and transgelin-2 correlates with FIB4 value.
RESULTS: Chemerin and RBP-4 were highly expressed in sera of all NAFLD, especially in obese individuals. Chemerin level was also linked to MS. High level of serum CK-18 fragments and transgelin-2 did not correlate with obesity and MS, but seemed to correlate with progression of NAFLD to liver fibrosis.
CONCLUSIONS: In conclusion, the production of the two adipokines, chemerin and RBP-4, is strongly associated with obesity in patients with NAFLD. Serum concentrations of CK-18 fragments and transgelin-2 correlate with the severity of NAFLD, but no with obesity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27740519     DOI: 10.5604/16652681.1222102

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  6 in total

Review 1.  Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders.

Authors:  William S Blaner
Journal:  Pharmacol Ther       Date:  2019-01-29       Impact factor: 12.310

Review 2.  Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).

Authors:  Ali Saeed; Robin P F Dullaart; Tim C M A Schreuder; Hans Blokzijl; Klaas Nico Faber
Journal:  Nutrients       Date:  2017-12-29       Impact factor: 5.717

3.  Components of metabolic syndrome in relation to plasma levels of retinol binding protein 4 (RBP4) in a cohort of people aged 65 years and older.

Authors:  M Majerczyk; P Kocełak; P Choręza; H Arabzada; A J Owczarek; M Bożentowicz-Wikarek; A Brzozowska; A Szybalska; M Puzianowska-Kuźnicka; T Grodzicki; A Więcek; M Olszanecka-Glinianowicz; J Chudek
Journal:  J Endocrinol Invest       Date:  2018-03-09       Impact factor: 4.256

Review 4.  Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis.

Authors:  Qian Ren; Hongya Wang; Yan Zeng; Xia Fang; Mei Wang; Dongze Li; Wei Huang; Yong Xu
Journal:  Lipids Health Dis       Date:  2022-03-02       Impact factor: 3.876

5.  Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.

Authors:  Yan Sun; Wenfang Peng; Weiwei He; Man Luo; Guilin Chang; Jiping Shen; Xiaoping Zhao; Yu Hu
Journal:  J Exp Clin Cancer Res       Date:  2018-07-24

6.  Serum Retinol-Binding Protein Levels Are Associated with Nonalcoholic Fatty Liver Disease in Chinese Patients with Type 2 Diabetes Mellitus: A Real-World Study.

Authors:  Zhi-Hui Zhang; Jiang-Feng Ke; Jun-Xi Lu; Yun Liu; Ai-Ping Wang; Lian-Xi Li
Journal:  Diabetes Metab J       Date:  2021-08-10       Impact factor: 5.376

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.